Table 5.
Cox regression models to evaluate the risk of disease activity based on CXCL13 CSF concentrations
| HR | 95% CIs | P | |
|---|---|---|---|
| Time to first relapse | |||
| CXCL13 low | 1.0 | Ref | |
| CXCL13 intermediate | 5.13 | 1.16–22.82 | 0.032 |
| CXCL13 high | 12.61 | 2.53–62.84 | 0.002 |
| Time to first MRI activity | |||
| CXCL13 low | 1.0 | Ref | |
| CXCL13 intermediate | 2.29 | 1.01–5.22 | 0.049 |
| CXCL13 high | 7.04 | 2.75–18.00 | < 0.001 |
| Time to disability progression | |||
| CXCL13 low | 1.0 | Ref | |
| CXCL13 intermediate | 2.13 | 0.19–23.43 | 0.536 |
| CXCL13 high | 7.02 | 0.63–78.31 | 0.113 |
| Time to first disease activity | |||
| CXCL13 low | 1.0 | Ref | |
| CXCL13 intermediate | 2.20 | 1.01–4.83 | 0.049 |
| CXCL13 high | 12.13 | 4.89–30.08 | < 0.001 |
HR, hazard ratio; 95% CIs, 95% confidence intervals. In bold are reported significant differences at a two-sided α level < 0.05. CSF, cerebrospinal fluid.